Transfusion of CMV-unselected blood components may lead to inappropriate donor selection for patients subsequently undergoing allogeneic stem cell transplant.
Suzy MortonR DanbyV RochaA PeniketM F MurphyPublished in: Transfusion medicine (Oxford, England) (2016)
Passive transfer of CMV IgG is an unanticipated consequence of transfusion of CMV-U products and has the potential to cause morbidity. Inaccurate recording of serostatus pre-transplant has wider implications for data reporting on transplant outcomes. When transfusing CMV-U components pre-transfusion CMV IgG samples must be taken and transfusion history must be considered when interpreting results.
Keyphrases
- cardiac surgery
- stem cells
- sickle cell disease
- end stage renal disease
- newly diagnosed
- ejection fraction
- acute kidney injury
- chronic kidney disease
- bone marrow
- type diabetes
- peritoneal dialysis
- machine learning
- big data
- adipose tissue
- metabolic syndrome
- climate change
- insulin resistance
- artificial intelligence
- cell therapy
- adverse drug
- patient reported
- data analysis